Manufacturing

J&J has begun scaling back its COVID-19 vaccine producation due to the falling demand for the jabs

Eli Lilly has announced plans to invest $450m in manufacturing facilities at Research Triangle Park in North Carolina, US

Daiichi Sankyo shares plans to build its first mRNA COVID-19 vaccine factory in Japan

Sarepta Therapeutics is a company focused on gene therapy, RNA and gene editing, engineering precision genetic medication for rare diseases. It has announced the signing of a commercial supply agreement with Catalent that will allow the company to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).

PBS Biotech, an innovative, single-use bioreactor manufacturer and process development services provider, has worked together with Avego Management and BroadOak Capital Partners to raise $22m in financing. It will be used to improve the company’s product portfolio, expand process development services and increase customer support for global cell therapy clients.

Sanofi is aiming to expand its eco-friendly and renewable energy ecosystem with plans to install solar panels on the car park, add electric vehicle charging points to the staff car park and gradually convert the corporate cars to electric vehicles over a longer period of time.

The FDA has removed approval for Eli Lilly's bebtelovimab due to its decreasing efficacy

Parthenon Therapeutics, a precision oncology company that is focusing on inventing a novel class of anti-cancer therapies to reprogramme the tumour microenvironment (TME), is collaborating with ImaginAb Inc, a global biotechnology company developing imaging agents and radiopharmaceutical therapies (RPT) products.

Lupin Healthcare have launched a carbon-neutral inhaler for adult asthma patients

South Africa’s Biovac has made its first batch of the mRNA shot. The company finished its first doses at its facility in Cape Town, according to Bloomberg.

The site aims to cut 40% of its greenhouse gas emissions by 2025

SpectrumX have announced recent changes to their state-of-the-art production facility in Knutsford, Cheshire. This has paved the way towards the production of its drug substance, SPC-069, for clinical trials, according to Proactive Investors.